Genetic markers of bevacizumab-induced hypertension

Angiogenesis

Volumn 17, Issue 3, 2014, Pages 685-694

  Lambrechts, Diether ^a,b   Moisse, Matthieu ^a,b   Delmar, Paul ^c   Miles, David W ^d   Leighl, Natasha ^e   Escudier, Bernard ^f   Van Cutsem, Eric ^g   Bansal, Aruna T ^h   Carmeliet, Peter ^a   Scherer, Stefan J ⁱ   De Haas, Sanne ^c   Pallaud, Celine ^c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b University of Leuven   (Belgium)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Acclarogen Ltd   (United Kingdom)

ⁱ GENENTECH INC   (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Hypertension; Predictive biomarker; Single nucleotide polymorphism

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR; PROTEIN KINASE WNK1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; GENETIC MARKER; MONOCLONAL ANTIBODY; PLACEBO;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; EGF GENE; EGLN3 GENE; FEMALE; FLT1 GENE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HYPERTENSION; KDR GENE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TUMOR GENE; VEGF A GENE; WNK1 GENE; BIOASSAY; CHEMICALLY INDUCED; DEMOGRAPHY; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; DEMOGRAPHY; ENDPOINT DETERMINATION; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903898750     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9424-7     Document Type: Article

References (52)

1. Maru D, Venook AP, Ellis LM (2013) Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res 19(11):2824-2827. doi: 10.1158/1078-0432.Ccr- 12-3409
2. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342. doi: 10.1056/NEJMoa032691
3. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-2019. doi: 10.1200/JCO.2007.14.9930
4. Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1
5. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550. doi: 10.1056/NEJMoa061884
6. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103-2111. doi: 10.1016/S0140-6736(07)61904-7
7. Miller K, Wang ML, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676. doi: 10.1056/Nejmoa072113
8. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252-1260. doi: 10.1200/Jco.2010.28.0982
9. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473-2483. doi: 10.1056/NEJMoa1104390
10. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484-2496. doi: 10.1056/NEJMoa1103799
11. Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: A Randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039-2045. doi: 10.1200/Jco.2012.42.0505
12. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745. doi: 10.1200/JCO.2008.16. 3055
13. des Guetz G, Uzzan B, Chouahnia K, Morere JF (2011) Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 6(4):197-202. doi: 10.1007/S11523-011-0204-7
14. Tang PA, Cohen SJ, Kollmannsberger C et al (2012) Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 18(21):6023-6031. doi: 10.1158/1078-0432.Ccr-11-3252
15. Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18(9):2658-2667. doi: 10.1158/1078-0432.Ccr-11-1900
16. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. AJH 23(5):460-468. doi: 10.1038/ajh.2010.25
17. Budai B, Nagy T, Lang I, Hitre E (2013) The use of high dose d, l-leucovorin in first-line bevacizumab+ treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab. Angiogenesis 16(1):113-121. doi: 10.1007/s10456-012-9303-z
18. Langenberg MH, van Herpen CM, De Bono J et al (2009) Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 27(36):6152-6159. doi: 10.1200/JCO.2009.22.2273
19. Izzedine H, Ederhy S, Goldwasser F et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807-815. doi: 10.1093/Annonc/Mdn713
20. Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980-982; discussion 980-982. doi: 10.1056/NEJMc052954
21. Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol-Chicago 63(10):1475-1478. doi: 10.1001/Archneur.63.10. 1475
22. Sunshine SB, Dallabrida SM, Durand E et al (2012) Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 109(28):11306-11311. doi: 10.1073/pnas.1203275109
23. Kruzliak P, Kovacova G, Pechanova O (2013) Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor- induced hypertension. Angiogenesis 16(2):289-295. doi: 10.1007/s10456-012-9327-4
24. Bouloumie A, Schini-Kerth VB, Busse R (1999) Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41(3):773-780. doi: 10.1016/S0008-6363(98)00228-4
25. Henry TD, Annex BH, McKendall GR et al (2003) The VIVA trial: vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107(10):1359-1365
26. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54(3):652-658. doi: 10.1161/HYPERTENSIONAHA.109.129973
27. Kamba T, Tam BY, Hashizume H et al (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290(2):H560-H576. doi: 10.1152/ajpheart.00133.2005
28. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672-4678. doi: 10.1200/JCO.2008.16.1612
29. Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27(13):2231-2237. doi: 10.1200/JCO.2008.20.0238
30. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27(8):1227-1234. doi: 10.1200/Jco.2007.14.5466
31. Reck M, von Pawel J, Zatloukal P et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804-1809. doi: 10.1093/annonc/mdq020
32. Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144-2150. doi: 10.1200/JCO.2009.26.7849
33. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-3247. doi: 10.1200/JCO.2008.21.6457
34. Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968-3976. doi: 10.1200/Jco.2011.36.2236
35. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31(9):1219-1230. doi: 10.1200/Jco.2012.46.2762
36. Lambrechts D, Claes B, Delmar P et al (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13(7):724-733. doi: 10.1016/S1470-2045(12)70231-0
37. Buysschaert I, Schmidt T, Roncal C, Carmeliet P, Lambrechts D (2008) Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med 12(6B):2533-2551. doi: 10.1111/j.1582-4934.2008.00515.x
38. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145):661-678. doi: 10.1038/nature05911
39. Conen D, Cheng S, Steiner LL, Buring JE, Ridker PM, Zee RY (2009) Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study. J Hypertens 27(3):476-483
40. Smith NL, Hindorff LA, Heckbert SR et al (2007) Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 297(5):489-498. doi: 10.1001/jama.297.5.489
41. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2004) 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 15(5):427-433
42. Reumers J, De Rijk P, Zhao H et al (2012) Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol 30(1):61-68. doi: 10.1038/nbt.2053
43. Barret JC (2009) Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 10:pdb.ip71. doi: 10.1101/pdb.ip71
44. Frey MK, Olvera N, Bogomolniy F, et al. (2008) WNK1 haplotypes and bevacizumab-induced hypertension. J Clin Oncol 26(15 Suppl):11003
45. Huang CL, Kuo E (2007) Mechanisms of disease: WNK-ing at the mechanism of salt-sensitive hypertension. Nat Clin Pract Nephrol 3(11):623-630. doi: 10.1038/ncpneph0638
46. Wilson FH, Disse-Nicodeme S, Choate KA et al (2001) Human hypertension caused by mutations in WNK kinases. Science 293(5532):1107-1112. doi: 10.1126/science.1062844
47. Newhouse S, Farrall M, Wallace C et al (2009) Polymorphisms in the WNK1 gene are associated with blood pressure variation and urinary potassium excretion. PLoS ONE 4(4):e5003. doi: 10.1371/journal.pone.0005003
48. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2005) WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 46(4):758-765. doi: 10.1161/01.HYP.0000186240.81996.57
49. Wang Y, Zheng Y, Zhang W et al (2007) Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50(8):760-767. doi: 10.1016/j.jacc.2007.04.074
50. Tanabe KK, Lemoine A, Finkelstein DM et al (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299(1):53-60. doi: 10.1001/jama.2007.65
51. Yoo BK, He P, Lee SJ, Yun CC (2011) Lysophosphatidic acid 5 receptor induces activation of Na(+)/H(+) exchanger 3 via apical epidermal growth factor receptor in intestinal epithelial cells. Am J Physiol Cell Physiol 301(5):C1008-C1016. doi: 10.1152/ajpcell.00231.2011
52. Beltowski J, Lowicka E (2009) EGF receptor as a drug target in arterial hypertension. Mini Rev Med Chem 9(5):526-538